Figure 1.
Figure 1. Treatment algorithm for lower-risk MDS. *Thrombopoietin agonists should only be used outside of a clinical trial in the setting of immune-mediated thrombocytopenia

Treatment algorithm for lower-risk MDS. *Thrombopoietin agonists should only be used outside of a clinical trial in the setting of immune-mediated thrombocytopenia

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal